Literature DB >> 28468008

Effect of Maxing Shigan Tang on H1N1 Influenza A Virus-Associated Acute Lung Injury in Mice.

Yanchun Zhong1, Jie Zhou, Ning Liang, Bihao Liu, Ruirui Lu, Yu He, Chunlin Liang, Junbiao Wu, Yuan Zhou, Miaomiao Hu, Jiuyao Zhou.   

Abstract

OBJECTIVE: This study is aimed at examining the effects of Maxing Shigan Tang (MST) treatment on H1N1-associated acute lung injury (ALI) and exploring the possible mechanism.
MATERIAL AND METHODS: Mice were randomly divided into a control group, model group, peroxisomal proliferator activator receptor γ (PPARγ) inhibition group (PPARγ-), PPARγ activation group (PPARγ+), and MST group. Influenza A (H1N1) virus of the Fort Monmouth 1 (FM1) strain was used to induce an ALI mice model. Hematoxylin and eosin staining was performed to investigate the effect of MST treatment on H1N1-associated ALI. Cell apoptosis of lung tissues of each group were conducted through transferase-mediated dUTP nick end-labeling methods. Moreover, the expression level of caspase 3, activity of caspase 3, and serum level of tumor necrosis factor (TNF)-α of each group were also analyzed. Finally, quantitative real-time polymerase chain reaction and Western blotting analysis were carried out to detect angiopoietin-like 4 (ANGPTL4) expression level.
RESULTS: We found that mice infected with the FM1 strain of H1N1 influenza A virus developed severe ALI, and MST could improve H1N1-induced ALI. Moreover, MST decreased lung cell apoptosis and reduced the serum content of TNF-α. In addition, MST significantly induced the ANGPTL4 expression in H1N1-induced ALI.
CONCLUSION: MST improves H1N1-associated ALI maybe through targeting ANGPTL4 in mice.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  H1N1 influenza A virus-associated acute lung injury; Maxing Shigan Tang; Mice

Year:  2017        PMID: 28468008     DOI: 10.1159/000458726

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  11 in total

1.  Treatment efficacy of Lianhua Qingwen capsules for eraly-stage COVID-19.

Authors:  Si-Jia Fan; Jian-Kun Liao; Liu Wei; Bai-Yu Wang; Liu Kai; Du-Xun Tan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

2.  Guideline-Based Chinese Herbal Medicine Treatment Plus Standard Care for Severe Coronavirus Disease 2019 (G-CHAMPS): Evidence From China.

Authors:  Yong-An Ye
Journal:  Front Med (Lausanne)       Date:  2020-05-27

3.  Ma xing shi gan decoction eliminates PM2.5-induced lung injury by reducing pulmonary cell apoptosis through Akt/mTOR/p70S6K pathway in rats.

Authors:  Yefang Wang; Bo Zhao; Yuxiang Fei; Qiyang Yin; Jianping Zhu; Guanghui Ren; Bowen Wang; Weirong Fang; Yunman Li
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

4.  Conventional Western Treatment Combined With Chinese Herbal Medicine Alleviates the Progressive Risk of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study.

Authors:  Tsai-Hui Lin; Shu-I Chen; Yuan-Chih Su; Mei-Chen Lin; Hung-Jen Lin; Sheng-Teng Huang
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

5.  Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis.

Authors:  Xiuli Sun; Jinhe Jiang; Yang Wang; Shuying Liu
Journal:  Eur J Integr Med       Date:  2020-10-29       Impact factor: 1.314

Review 6.  Research progress of traditional Chinese medicine against COVID-19.

Authors:  Wei Ren; Pan Liang; Yue Ma; Qin Sun; Qingrong Pu; Li Dong; Gang Luo; Maryam Mazhar; Jiali Liu; Raoqiong Wang; Sijin Yang
Journal:  Biomed Pharmacother       Date:  2021-02-03       Impact factor: 7.419

7.  Diammonium glycyrrhizinate lipid ligand ameliorates lipopolysaccharide-induced acute lung injury by modulating vascular endothelial barrier function.

Authors:  Mei-Mei Liu; Jin Zhou; Dan Ji; Jun Yang; Yan-Ping Huang; Qi Wang
Journal:  Exp Ther Med       Date:  2021-01-29       Impact factor: 2.447

Review 8.  Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects.

Authors:  Liu-Cheng Li; Zhi-Hui Zhang; Wen-Cheng Zhou; Jie Chen; Hua-Qian Jin; Hong-Mei Fang; Qin Chen; Ye-Cheng Jin; Jiao Qu; Lian-Di Kan
Journal:  Biomed Pharmacother       Date:  2020-08-19       Impact factor: 6.529

9.  Preliminary study of Yinhuapinggan granule against H1N1 influenza virus infection in mice through inhibition of apoptosis.

Authors:  Hai-Xia Du; Hui-Fen Zhou; Jie-Hong Yang; Yi-Yu Lu; Yu He; Hai-Tong Wan
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

10.  The effects of the Xijiao Dihuang decoction combined with Yinqiao powder on miRNA-mRNA profiles in mice infected with influenza a virus.

Authors:  Ke Li; Xiaoming Chen; Jing Zhong; Hehe Ye; Shujing Zhang; Dongyu Ge; Xudan Wang; Ying Wu
Journal:  BMC Complement Med Ther       Date:  2020-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.